Want to see ELAB full AI Analyst Report?
ELAB Stock Chart & Stats
$6.05
-$0.19(-8.12%)
At close: 4:00 PM EST
$6.05
-$0.19(-8.12%)
Day’s Range― - ―
52-Week Range$5.24 - $2,671.20
Previous CloseN/A
Volume180.10K
Average Volume (3M)89.87K
Market Cap
$4.61M
Enterprise Value-$1.30
Total Cash (Recent Filing)$18.79M
Total Debt (Recent Filing)$13.92M
Price to Earnings (P/E)―
Beta2.81
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding809,584
10 Day Avg. Volume35,159
30 Day Avg. Volume89,868
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)4.90
P/FCF Ratio-0.45
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthThe sharp increase in trailing revenue indicates expanding commercial activity and possible traction across the company’s businesses. Sustaining this growth could improve operating leverage over time, although current profitability remains unproven.
Exclusive Aerospace Defense IPExclusive worldwide rights can provide a differentiated technology base and support future aerospace and defense product development. The license may strengthen market positioning, though commercialization depends on milestones, funding and customer adoption.
AI-Enabled Drug Discovery ProgressPositive laboratory results provide early validation for the company’s AI-enabled discovery strategy and create a clearer development path for muscle-preservation programs. The platform could generate pipeline value if later models and clinical studies confirm efficacy.
Bears Say
Severe Profitability DeteriorationThe collapse in gross margin alongside substantial operating and net losses shows that revenue growth is not yet translating into a sustainable economic model. Persistent losses may restrict investment capacity and require continued external financing.
Persistent Cash BurnOngoing negative operating and free cash flow means the business is not funding its needs internally. Continued cash consumption increases dependence on equity, debt or strategic financing, potentially limiting execution and increasing dilution or repayment risk.
Rising Leverage And Negative ReturnsHigher leverage combined with deeply negative returns indicates weakening balance-sheet quality and limited capital efficiency. This reduces financial flexibility, raises dependence on financing markets and could make it harder to fund long-cycle biotech and aerospace initiatives.
PMGC Holdings News
ELAB FAQ
What was PMGC Holdings’s price range in the past 12 months?
PMGC Holdings lowest stock price was $5.24 and its highest was $2671.20 in the past 12 months.
What is PMGC Holdings’s market cap?
PMGC Holdings’s market cap is $4.61M.
When is PMGC Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PMGC Holdings’s earnings last quarter?
Currently, no data Available
Is PMGC Holdings overvalued?
According to Wall Street analysts PMGC Holdings’s price is currently Overvalued.
Does PMGC Holdings pay dividends?
PMGC Holdings does not currently pay dividends.
What is PMGC Holdings’s EPS estimate?
PMGC Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PMGC Holdings have?
PMGC Holdings has 809,584 shares outstanding.
What happened to PMGC Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PMGC Holdings?
Currently, no hedge funds are holding shares in ELAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PMGC Holdings
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
CNS Pharmaceuticals
―
Ownership Overview
41.21%
Insiders
― Other Institutional Investors
58.58% Public Companies and
Individual Investors